XBI vs. IBB
XBI (SPDR S&P Biotech ETF) and IBB (iShares Nasdaq Biotechnology ETF) are both Health & Biotech Equities funds - XBI tracks the S&P Biotechnology Select Industry Index while IBB tracks the NASDAQ Biotechnology Index. Both are passively managed. Over the past 10 years, XBI returned 9.90%/yr vs 7.49%/yr for IBB. Their correlation of 0.91 suggests significant overlap in exposure. XBI charges 0.35%/yr vs 0.47%/yr for IBB.
Performance
XBI vs. IBB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XBI achieves a 11.00% return, which is significantly higher than IBB's 1.67% return. Over the past 10 years, XBI has outperformed IBB with an annualized return of 9.90%, while IBB has yielded a comparatively lower 7.49% annualized return.
XBI
- 1D
- -0.78%
- 1M
- 3.56%
- YTD
- 11.00%
- 6M
- 11.29%
- 1Y
- 62.93%
- 3Y*
- 15.78%
- 5Y*
- 0.25%
- 10Y*
- 9.90%
IBB
- 1D
- -0.42%
- 1M
- 2.78%
- YTD
- 1.67%
- 6M
- 2.07%
- 1Y
- 34.44%
- 3Y*
- 9.60%
- 5Y*
- 1.78%
- 10Y*
- 7.49%
XBI vs. IBB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 11.00% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
IBB iShares Nasdaq Biotechnology ETF | 1.67% | 27.98% | -2.41% | 3.76% | -13.69% | 0.95% | 26.01% | 25.42% | -9.53% | 21.08% |
Correlation
The correlation between XBI and IBB is 0.91, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.91 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.91 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.89 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.91 |
Correlation (All Time) Calculated using the full available price history since Feb 6, 2006 | 0.91 |
The correlation between XBI and IBB has been stable across timeframes, ranging from 0.89 to 0.91 - a consistent structural relationship.
XBI vs. IBB - Sectors Allocation Comparison
Sectors
XBI
IBB
Healthcare
Financial Services
-
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
XBI
IBB
Financial Services
XBI
IBB
-
Basic Materials
XBI
IBB
-
Communication Services
XBI
-
IBB
-
Consumer Cyclical
XBI
-
IBB
-
Consumer Defensive
XBI
-
IBB
-
Energy
XBI
-
IBB
-
Industrials
XBI
-
IBB
-
Real Estate
XBI
-
IBB
-
Technology
XBI
-
IBB
-
Utilities
XBI
-
IBB
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XBI vs. IBB — Risk / Return Rank
XBI
IBB
XBI vs. IBB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XBI | IBB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.72 | ||
| Sortino ratioReturn per unit of downside risk | +0.80 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.29 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 6.51 | 3.59 | +2.92 |
| Martin ratioReturn relative to average drawdown | 19.22 | 11.07 | +8.15 |
Loading charts...
Drawdowns
XBI vs. IBB - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, roughly equal to the maximum IBB drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for XBI and IBB.
Loading charts...
Drawdown Indicators
| XBI | IBB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -62.85% | -1.04% |
Max Drawdown (1Y)Largest decline over 1 year | -9.72% | -9.63% | -0.09% |
Max Drawdown (3Y)Largest decline over 3 years | -32.99% | -24.85% | -8.14% |
Max Drawdown (5Y)Largest decline over 5 years | -54.71% | -39.82% | -14.89% |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | -39.82% | -24.07% |
Current DrawdownCurrent decline from peak | -21.78% | -3.41% | -18.37% |
Average DrawdownAverage peak-to-trough decline | -20.93% | -21.15% | +0.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.29% | 3.13% | +0.16% |
Volatility
XBI vs. IBB - Volatility Comparison
SPDR S&P Biotech ETF (XBI) has a higher volatility of 10.06% compared to iShares Nasdaq Biotechnology ETF (IBB) at 7.24%. This indicates that XBI's price experiences larger fluctuations and is considered to be riskier than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XBI | IBB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.06% | 7.24% | +2.82% |
Volatility (6M)Calculated over the trailing 6-month period | 20.85% | 15.86% | +4.99% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.14% | 20.34% | +5.80% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.22% | 22.00% | +10.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.02% | 23.23% | +8.79% |
XBI vs. IBB - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than IBB's 0.47% expense ratio.
Dividends
XBI vs. IBB - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.33%, more than IBB's 0.24% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.24% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
XBI SPDR S&P Biotech ETF | 0.33% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
With a correlation of 0.91, XBI and IBB move almost identically. Holding both adds very little diversification - you're essentially doubling your position in the same market segment. Choosing one is usually more capital-efficient.
XBI has higher volatility (10.06%) compared to IBB (7.24%). In terms of maximum drawdown, XBI dropped -63.89% vs IBB's -62.85%.
On 10-year performance, XBI leads with 9.90% vs 7.49% for IBB. On fees, XBI is cheaper at 0.35% per year. On volatility, IBB has been the lower-risk option at 7.24%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, XBI has performed better with a 9.90% return vs 7.49%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XBI is cheaper with a 0.35% expense ratio, compared with 0.47% for IBB.
XBI has the higher dividend yield at 0.33%, compared with 0.24% for IBB.
XBI tracks S&P Biotechnology Select Industry Index, while IBB tracks NASDAQ Biotechnology Index. They also come from different issuers: State Street and iShares. Their fees differ too: 0.35% for XBI and 0.47% for IBB.
XBI currently has the higher Sharpe Ratio (2.42 vs 1.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XBI and IBB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer